Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2013 New trial record